← All trials
NCT06271772
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2024
- Primary completion
- Jul 1, 2025
- Completion date
- Dec 31, 2025
- First posted
- Feb 22, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOfficial
- Aravind Eye HospitalCollaborator
- Stanford UniversityOfficial
- Federal University of Sao PauloCollaborator
- Stanford UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.